.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB24_Pegzilarginase.Pegzilarginase .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB24_Pegzilarginase.Pegzilarginase| name: | Pegzilarginase |
| ATC code: | A16AB24 | route: | intravenous |
| n-compartments | 2 |
Pegzilarginase is a recombinant human arginase 1 enzyme, covalently modified with polyethylene glycol (PEG), developed as an enzyme replacement therapy for the treatment of arginase 1 deficiency, a rare inherited disorder of the urea cycle. It is under clinical investigation, primarily for rare metabolic disorders, and is not approved for general therapeutic use as of 2024.
Population pharmacokinetic parameters in adult and pediatric patients with arginase 1 deficiency, following intravenous administration. Most PK assessments are from clinical trials in subjects with this rare genetic disorder.